FEELM
21.11.2022 13:48:38 CET | Business Wire | Press release
FEELM, the flagship atomization technology platform belonging to SMOORE - the world’s largest vape manufacturer, has won Best Innovation in the Vaping Industry and Sustainable Vaping Award at the UKVIA Industry Forum.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221121005487/en/
FEELM won the UKVIA Best Innovation Award. (Photo: Business Wire)
UKVIA is one of the world's most influential trade associations for the vaping sector. It is also one of the most accredited industrial association in Europe. This is the first time they held an award competition ever since their establishment in 2016. The competition is consisted of three sessions: online application, audiences review, and experts scoring. FEELM Max won the victory after rounds of assessments of more than 300 audiences and 10 experts.
The Best Innovation in the Vaping Industry
The Best Innovation in the Vaping Industry recognized the significant contribution FEELM has made to vaping innovation, particularly its world's first ceramic coil disposable pod solution FEELM Max.
FEELM Max has made a number of breakthrough innovations, including more puffs with the same e-liquid volume versus other coil technologies. Despite heating the same e-liquid volume as other conventional devices, puff numbers increase by more than 25%. FEELM Max achieves a flavour consistency of over 95% as well as a smoother vapour – and there is no dry burning – thanks to Constant Output Control and our Patented Flavour-Lock Technologies. Not only is FEELM Max enhancing the vaping experience, but it is also outperforming other disposables on harm reduction by almost 50%.
To stand still on the path of innovation, FEELM has established China’s first PMTA-standard testing lab besides the now-existing 14 labs globally, to empower our clients facing with the stringent regulations on the industry. This is to prove our determination to drive innovation with technology, and keep providing products with enhanced quality to consumers.
The Sustainable Vaping Award
The Sustainable Vaping Award was given in recognition of FEELM excelling in three key areas: creating sustainable advanced technologies and products; using responsible marketing; and embracing a greener future.
FEELM is credited with building the world's first environmentally friendly disposable electronic atomization device in 2019. In 2022, the world's first ceramic coil disposable pod "FEELM Max" was created and the "FEELM GREEN" series was launched based on it. This series is FEELM Max's main environmental protection solutions, its latest "product is packaging" series has been presented at the major European electronic atomization exhibition, aroused the industry's high attention. In addition, FEELM also created an environmentally friendly zero nicotine e-atomization device this year.
It was also acknowledged that its brand website and social media platforms go to great lengths to restrict those who are under the legal age of vaping to prevent them from accessing any information about electronic atomization products; and that FEELM conducts regular satisfaction surveys on behalf of clients so data can be used to improve customer experience.
FEELM has announced its launching of the Carbon Disclosure Project (CDP), committing to achieve carbon neutrality by 2050, and its automated factory has adopted an energy management system with the purpose of decreasing carbon emissions whilst increasing energy consumption efficiency
The Award is also recognition of FEELM’s cut in carbon emissions of over 500 tons in the last six months, and its aim to lower greenhouse gas emissions and achieve Scope 1 and Scope 2 carbon neutrality by 2050. The company intends to achieve this by improving energy efficiency and increasing the use of renewable energy sources to 30% of total consumption by 2030 and has accordingly introduced a professional carbon neutral energy screening team and internal resources to monitor carbon consumption improvement. It has also partnered with a third-party cleaning company to collect non-hazardous waste for recycling, which in 2020 helped clients reduce single-use plastics by 100 tons – equivalent to 4 million plastic bottles, while in 2021 it reduced its water consumption by 9.4% year-on-year.
Echo liu, FEELM Europe Division Director said:
“We are delighted to have won both awards and honoured by the recognition the UKVIA have given us.”
“A number of leading vaping brands are driven by FEELM Technology, and our vaping devices loaded with FEELM atomizer are now being exported to over 50 countries and regions.”
“FEELM can only realize its corporate vision – “atomization makes life better” – by being sustainable and creating value for society. Every day we move a step closer to this goal by creating sustainable advanced technologies and products, using responsible marketing, and embracing a greener future.”
For more information or journalist queries, please contact us via feelm@smooretech.com.
About FEELM:
As a flagship tech brand belonging to SMOORE, FEELM is the world’s leading closed vape system solution provider. Based on the world's leading Ceramic Coil Heating Technology, FEELM combines authentic Flavor Reproduction Technology with innovative electronics technology, bringing ultimate sensation and premium vaping experience.
About SMOORE:
SMOORE is a global leader in offering vaping technology solutions, including manufacturing vaping devices, and vaping components for HNB products on an ODM basis, with advanced R&D technology, strong manufacturing capacity, wide-spectrum product portfolio and diverse customer base.
According to Frost & Sullivan, SMOORE is the world’s largest vaping device manufacturer in terms of revenue, accounting for 22.8% of the total global market share in 2021. Its global market share is bigger than the sum of those listed from No.2 to No.5.
About the UKVIA:
The UK Vaping Industry Association (UKVIA) is the #1 trade association for the vaping sector supporting, developing, and promoting the £1bn vaping industry, the UK’s largest growing consumer goods sector. Its vision is a world where the evidence-based, life-changing public health benefits of vaping products are fully understood so that their positive impact can be maximised.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221121005487/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
First Randomized Controlled Trial Shows Promise of a Ketogenic Diet in Psychotic Disorders8.7.2026 15:00:00 CEST | Press release
Trial reports correlations between ketone levels and cognitive and psychiatric symptoms in individuals with schizophrenia-spectrum and bipolar-1 disorders Published today in Schizophrenia Bulletin, a first-of-its-kind randomized controlled trial (RCT) from researchers at the University of California, San Francisco (UCSF), and funded in part by the National Institute of Mental Health (NIMH), adds to growing literature on the potential benefit of a ketogenic diet for treating psychotic disorders. The study, which enrolled participants with schizophrenia-spectrum or bipolar-1 disorders, demonstrated rapid metabolic improvements with a ketogenic diet compared to diet-as-usual during an initial one-month RCT open-label phase. Furthermore, those who continued with the optional four-month single-arm ketogenic diet extension saw meaningful gains across metabolic, psychiatric, and cognitive measures. This press release features multimedia. View the full release here: https://www.businesswire.co
Teamily AI Publicly Launches Human+AI Social Platform to Make Building and Growing a Company Easy for Every Team8.7.2026 15:00:00 CEST | Press release
Teamily AI (https://Teamily.ai), together with its Agentic AI Infra platform TensorOpera AI (https://TensorOpera.ai), today announced the public launch of its Human+AI social platform, a product stack that has already served more than 5 million users around the world. Starting today in Palo Alto and rolling out simultaneously across dozens of countries, this first public launch opens the full stack to everyone with a single mission: to make building and growing a company easy for every person and every team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708584390/en/ "This is the moment we open our doors to the world," said co-founders Dr. Aiden Chaoyang He and Professor Salman Avestimehr. "We want every person and every team to be able to move from idea to product, from product to market, and from market to growth and investment, with an AI-native team by their side." At its core, Teamily AI enables humans and AI agents
Leo Cancer Care Raises $65M Series D to Scale Its Integrated Upright Cancer Care Platform8.7.2026 14:30:00 CEST | Press release
Oversubscribed round follows the world-first compact upright proton treatment at Stanford Medicine — funding a single upright platform that will span imaging and treatment across multiple radiation modalities. Leo Cancer Care, the medical technology company working to reinvent how patients are imaged and treated by designing systems around the body’s natural upright position, today announced the close of an oversubscribed $65 million Series D financing. The round was led by Silicon Valley’s Yu Galaxy and welcomes new investors including Eventide Asset Management, alongside continued support from the company’s existing investors. Leading cancer institutions are already adopting the upright approach. Stanford Medicine delivered the world’s first compact upright proton therapy treatment on 4 June 2026. Dana-Farber Cancer Institute and McLaren Health Care are among the institutions bringing the upright platform into their programmes — adoption that spans world-leading academic centers and
LUMI AI Factory Selects IQM to Deploy Advanced Quantum Computer, Accelerating Hybrid HPC and AI Development8.7.2026 14:00:00 CEST | Press release
The Halocene H4 quantum computer, named LUMI-IQ, will be delivered and installed in 2027 The system will be hosted at CSC – IT Center for Science in Finland and integrated into the LUMI AI Factory The system will provide researchers, industry innovators, and developers across Europe with a unique, advanced experimental platform where quantum computing and artificial intelligence converge The LUMI AI Factory, led by CSC – IT Center for Science, has selected IQM Quantum Computers (Nasdaq: IQMX) to deliver IQM Halocene H4, an advanced quantum computer aimed at accelerating hybrid high-performance computing, artificial intelligence, and quantum computing capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708006791/en/ LUMI AI Factory selects IQM to deploy advanced quantum computer, accelerating hybrid HPC and AI development IQM Halocene H4 is the first and most advanced on-premises superconducting quantum computer o
Merck Announces FDA Breakthrough Therapy Designation for Enpatoran in Lupus Patients With Active Skin Manifestations8.7.2026 14:00:00 CEST | Press release
Enpatoran could address a significant unmet need in lupus, specifically targeting cutaneous manifestations of the disease, which currently have no approved therapiesFDA's decision was supported by Phase 2 WILLOW study results, which demonstrated meaningful symptoms improvement, particularly among patients with active cutaneous manifestationsEnpatoran's potential to go beyond current treatment standards in lupus prompted FDA´s breakthrough designation, which is designed to expedite drug development and reviewNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to enpatoran for the treatment of lupus with active cutaneous manifestations. Enpatoran is an oral selective toll-like receptor (TLR) 7/8 inhibitor, designed to modulate pathways central to lupus-related inflammation. “For the 85% of lupus patients whose disease includes skin manif
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom